The Society for Immunotherapy of Cancer (SITC) has established the Cancer Immune Responsiveness Task Force whose mission is to explore and increase understanding of immune responsiveness by bringing together leaders in immunology, cell biology, genetics, computational biology and other relevant areas.
Building upon the success of 2018’s Interim Workshop on Cancer Immune Responsiveness (CIR), the goal of this year’s CIR workshop is the continued advancement of knowledge in the field about interactions between the immune system and cancer that contribute to immunotherapy response and resistance.Over this two-day workshop, participants will take part in both didactic sessions and working groups to identify and address key questions in the field concerning cancer immune responsiveness.Topics to be discussed include:
On May 23, 2019, members of the SITC Cancer Immune Responsiveness Task Force published Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop in the Journal for ImmunoTherapy of Cancer (JITC). The manuscript reports out progress achieved as a result of the 2018 Cancer Immune Responsiveness Workshop.
Tumor immunology has changed the landscape of cancer treatment, but cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The SITC CIR Task Force was the driving force behind the workshop held in 2018 aimed at identifying the fundamental questions of CIR, as a first milestone in the path toward a more contemporary understanding of CIR. This manuscript summarizes the contributions from working groups aiming at each CIR-related field including: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional Contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that Modulate CIR, and 5) Experimental Models that Best Represent CIR. In the upcoming follow-up workshop on Sept. 4-5, 2019, the Task Force will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations.
The Cancer Immune Responsiveness Task Force hosted a two-day workshop that brought together stakeholders to discuss topics including:
Access Program MaterialsEnduring materials from this program are available to the general public. Click here to access presentations to the program. Presentations and video recordings are available based on permission from presenters.
2018 Co-Chairs: Transcriptional Patterns of Distinct Immune LandscapesKwok-Kin Wong, MD, PhDNew York Langone HealthStephanie Spranger, PhDKoch Institute for Integrative Cancer Research at MIT
HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, ...
Autoimmune polyendocrine syndrome type II (APS-2) is a rare constellation of autoimmune hypoadrenalism, thyroid dysfunction and/or type 1 diabetes (T1DM), usually occurring in the 3rd or 4th decades and ...
Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to ...
Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ...
Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that play an important role in immune evasion, PD-1/PD-L1 inhibitor tolerance and tumour progression. Therefore, MDSCs are potential ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org